Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.40
AGN's Cash to Debt is ranked lower than
74% of the 790 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.44 vs. AGN: 0.40 )
Ranked among companies with meaningful Cash to Debt only.
AGN' s Cash to Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.4 Max: 25.09
Current: 0.4
0.02
25.09
Equity to Asset 0.63
AGN's Equity to Asset is ranked higher than
50% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. AGN: 0.63 )
Ranked among companies with meaningful Equity to Asset only.
AGN' s Equity to Asset Range Over the Past 10 Years
Min: 0.27  Med: 0.58 Max: 0.75
Current: 0.63
0.27
0.75
WACC vs ROIC
8.24%
-0.51%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -12.08
AGN's Operating margin (%) is ranked lower than
79% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.64 vs. AGN: -12.08 )
Ranked among companies with meaningful Operating margin (%) only.
AGN' s Operating margin (%) Range Over the Past 10 Years
Min: -36.27  Med: 6.95 Max: 14.13
Current: -12.08
-36.27
14.13
Net-margin (%) 100.04
AGN's Net-margin (%) is ranked higher than
99% of the 737 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.21 vs. AGN: 100.04 )
Ranked among companies with meaningful Net-margin (%) only.
AGN' s Net-margin (%) Range Over the Past 10 Years
Min: -28.83  Med: 5.67 Max: 102.76
Current: 100.04
-28.83
102.76
ROE (%) 18.53
AGN's ROE (%) is ranked higher than
80% of the 763 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.92 vs. AGN: 18.53 )
Ranked among companies with meaningful ROE (%) only.
AGN' s ROE (%) Range Over the Past 10 Years
Min: -11.23  Med: 7.32 Max: 19.24
Current: 18.53
-11.23
19.24
ROA (%) 10.84
AGN's ROA (%) is ranked higher than
79% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.58 vs. AGN: 10.84 )
Ranked among companies with meaningful ROA (%) only.
AGN' s ROA (%) Range Over the Past 10 Years
Min: -4.32  Med: 4.03 Max: 22.05
Current: 10.84
-4.32
22.05
ROC (Joel Greenblatt) (%) -35.31
AGN's ROC (Joel Greenblatt) (%) is ranked lower than
78% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.01 vs. AGN: -35.31 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AGN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -112.05  Med: 20.42 Max: 38.44
Current: -35.31
-112.05
38.44
Revenue Growth (3Y)(%) 27.40
AGN's Revenue Growth (3Y)(%) is ranked higher than
90% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.50 vs. AGN: 27.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AGN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -14  Med: 16.2 Max: 27.4
Current: 27.4
-14
27.4
EBITDA Growth (3Y)(%) 40.20
AGN's EBITDA Growth (3Y)(%) is ranked higher than
85% of the 575 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.50 vs. AGN: 40.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AGN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -39.9  Med: 3.6 Max: 40.2
Current: 40.2
-39.9
40.2
EPS Growth (3Y)(%) -1.20
AGN's EPS Growth (3Y)(%) is ranked lower than
63% of the 539 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.30 vs. AGN: -1.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
AGN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -27.1  Med: -0.1 Max: 19.7
Current: -1.2
-27.1
19.7
GuruFocus has detected 5 Warning Signs with Allergan PLC $AGN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AGN's 10-Y Financials

Financials (Next Earnings Date: 2017-02-22)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

AGN Guru Trades in Q1 2016

Jerome Dodson 40,000 sh (New)
Seth Klarman 1,721,587 sh (New)
Steve Mandel 1,789,239 sh (New)
Ron Baron 27,278 sh (+132.11%)
Lee Ainslie 1,410,362 sh (+107.43%)
Eric Mindich 1,875,073 sh (+97.67%)
Paul Tudor Jones 100,489 sh (+97.59%)
David Tepper 279,109 sh (+86.07%)
Wallace Weitz 304,722 sh (+55.34%)
Paul Singer 2,497,051 sh (+23.59%)
Mario Gabelli 39,798 sh (+18.90%)
Pioneer Investments 700,680 sh (+10.76%)
David Carlson 370,000 sh (+8.82%)
David Einhorn 437,200 sh (+6.63%)
Diamond Hill Capital 60,724 sh (+6.25%)
Vanguard Health Care Fund 11,187,547 sh (+2.05%)
John Hussman 5,000 sh (unchged)
Alan Fournier 500,000 sh (unchged)
Paul Tudor Jones 140,000 sh (unchged)
Paul Singer 770,000 sh (unchged)
John Paulson 214,700 sh (unchged)
Jim Simons Sold Out
Louis Moore Bacon Sold Out
First Pacific Advisors Sold Out
Steven Cohen Sold Out
John Paulson 5,418,300 sh (-2.07%)
Ken Fisher 3,225 sh (-2.45%)
Private Capital 161,728 sh (-2.58%)
Signature Select Canadian Fund 34,300 sh (-3.11%)
Ruane Cunniff 1,025,555 sh (-5.55%)
RS Investment Management 330,590 sh (-6.29%)
Daniel Loeb 5,000,000 sh (-7.41%)
Bernard Horn 17,389 sh (-15.95%)
Andreas Halvorsen 4,881,957 sh (-18.34%)
John Griffin 1,502,700 sh (-24.87%)
Leon Cooperman 561,265 sh (-28.21%)
Jeremy Grantham 188,267 sh (-33.24%)
Scott Black 4,905 sh (-34.19%)
Alan Fournier 500,000 sh (-34.71%)
First Eagle Investment 371,770 sh (-44.51%)
George Soros 143,277 sh (-60.79%)
Jana Partners 446,893 sh (-61.63%)
Joel Greenblatt 14,367 sh (-65.99%)
Eaton Vance Worldwide Health Sciences Fund 341,025 sh (-0.58%)
» More
Q2 2016

AGN Guru Trades in Q2 2016

Jeff Auxier 1,050 sh (New)
John Burbank 708,071 sh (New)
Robert Bruce 25,000 sh (New)
Carl Icahn 3,400,000 sh (New)
David Tepper 1,260,809 sh (+351.73%)
Jerome Dodson 102,000 sh (+155.00%)
Alan Fournier 1,171,614 sh (+134.32%)
Wallace Weitz 595,961 sh (+95.58%)
Mario Gabelli 60,913 sh (+53.06%)
RS Investment Management 489,611 sh (+48.10%)
Joel Greenblatt 20,529 sh (+42.89%)
Scott Black 6,365 sh (+29.77%)
Pioneer Investments 888,950 sh (+26.87%)
Leon Cooperman 671,212 sh (+19.59%)
Seth Klarman 2,001,978 sh (+16.29%)
David Carlson 430,000 sh (+16.22%)
Ken Fisher 3,594 sh (+11.44%)
Paul Singer 2,735,000 sh (+9.53%)
Vanguard Health Care Fund 12,066,307 sh (+7.85%)
Diamond Hill Capital 62,502 sh (+2.93%)
Daniel Loeb 500,000 sh (unchged)
John Burbank 90,000 sh (unchged)
Alan Fournier 1,100,000 sh (unchged)
Louis Moore Bacon 12,000 sh (unchged)
Paul Singer 3,000,300 sh (unchged)
John Paulson 214,700 sh (unchged)
Bernard Horn 17,389 sh (unchged)
John Hussman Sold Out
First Eagle Investment Sold Out
Jeremy Grantham Sold Out
Jana Partners Sold Out
Eric Mindich Sold Out
Steve Mandel Sold Out
David Einhorn Sold Out
Daniel Loeb 4,900,000 sh (-2.00%)
Private Capital 137,319 sh (-15.09%)
John Paulson 3,948,451 sh (-27.13%)
Lee Ainslie 878,319 sh (-37.72%)
George Soros 80,735 sh (-43.65%)
Ron Baron 13,923 sh (-48.96%)
John Griffin 700,900 sh (-53.36%)
Andreas Halvorsen 1,939,703 sh (-60.27%)
Paul Tudor Jones 34,942 sh (-65.23%)
Ruane Cunniff 3,435 sh (-99.67%)
Eaton Vance Worldwide Health Sciences Fund 273,025 sh (-19.94%)
» More
Q3 2016

AGN Guru Trades in Q3 2016

Manning & Napier Advisors, Inc 10,510 sh (New)
Tom Gayner 2,000 sh (New)
Jeff Auxier 6,750 sh (+542.86%)
John Griffin 1,259,200 sh (+79.65%)
Ron Baron 17,109 sh (+22.88%)
Ken Fisher 4,024 sh (+11.96%)
Pioneer Investments 982,212 sh (+10.49%)
Signature Select Canadian Fund 36,100 sh (+5.25%)
David Carlson 450,000 sh (+4.65%)
Jerome Dodson 104,500 sh (+2.45%)
Wallace Weitz 609,963 sh (+2.35%)
Scott Black 6,405 sh (+0.63%)
Eaton Vance Worldwide Health Sciences Fund 350,880 sh (+28.52%)
Louis Moore Bacon 12,000 sh (unchged)
Alan Fournier 1,100,000 sh (unchged)
Seth Klarman 2,001,978 sh (unchged)
Paul Singer 2,735,000 sh (unchged)
Paul Singer 2,099,700 sh (unchged)
George Soros 80,735 sh (unchged)
John Paulson 214,700 sh (unchged)
Robert Bruce 25,000 sh (unchged)
Bernard Horn 17,389 sh (unchged)
Lee Ainslie Sold Out
Andreas Halvorsen Sold Out
Joel Greenblatt Sold Out
Vanguard Health Care Fund 11,917,739 sh (-1.23%)
John Paulson 3,891,134 sh (-1.45%)
Private Capital 134,667 sh (-1.93%)
David Tepper 1,218,309 sh (-3.37%)
Mario Gabelli 55,988 sh (-8.09%)
Ruane Cunniff 3,075 sh (-10.48%)
Diamond Hill Capital 52,179 sh (-16.52%)
Leon Cooperman 541,122 sh (-19.38%)
Paul Tudor Jones 27,428 sh (-21.50%)
Daniel Loeb 3,785,000 sh (-22.76%)
Alan Fournier 621,214 sh (-46.98%)
John Burbank 375,134 sh (-47.02%)
Carl Icahn 425,438 sh (-87.49%)
» More
Q4 2016

AGN Guru Trades in Q4 2016

First Eagle Investment 26,600 sh (New)
First Pacific Advisors 16,500 sh (New)
Steven Cohen 84,101 sh (New)
NWQ Managers 280,596 sh (New)
Joel Greenblatt 116,791 sh (New)
Tom Gayner 14,000 sh (+600.00%)
David Tepper 4,261,406 sh (+249.78%)
Seth Klarman 3,432,603 sh (+71.46%)
Jerome Dodson 170,000 sh (+62.68%)
Scott Black 8,147 sh (+27.20%)
Pioneer Investments 1,229,649 sh (+25.19%)
Mario Gabelli 68,848 sh (+22.97%)
John Griffin 1,539,500 sh (+22.26%)
Paul Tudor Jones 31,400 sh (+14.48%)
Private Capital 149,819 sh (+11.25%)
Vanguard Health Care Fund 12,649,139 sh (+6.14%)
Wallace Weitz 637,733 sh (+4.55%)
Diamond Hill Capital 53,883 sh (+3.27%)
Ken Fisher 4,048 sh (+0.60%)
David Carlson 450,000 sh (unchged)
Robert Bruce 25,000 sh (unchged)
Paul Singer 2,735,000 sh (unchged)
Paul Singer 1,000,000 sh (unchged)
Carl Icahn 425,438 sh (unchged)
John Paulson 214,700 sh (unchged)
Daniel Loeb Sold Out
Ruane Cunniff Sold Out
John Burbank Sold Out
Alan Fournier Sold Out
George Soros 77,135 sh (-4.46%)
Manning & Napier Advisors, Inc 9,880 sh (-5.99%)
John Paulson 3,554,734 sh (-8.65%)
Ron Baron 14,572 sh (-14.83%)
Leon Cooperman 363,788 sh (-32.77%)
Eaton Vance Worldwide Health Sciences Fund 321,548 sh (-8.36%)
» More
» Details

Insider Trades

Latest Guru Trades with AGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Allergan PLC

SymbolPriceYieldDescription
AGNPRA862.776.375 1/2 % Cum.Conv.Pref.Shs 2015-1.3.18 Series -A-

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412 
Compare:OTCPK:TKPYY, NYSE:TEVA, NYSE:ZTS, NAS:MYL, OTCPK:SGIOF, OTCPK:ESALY, OTCPK:MKGAY, NYSE:PRGO, OTCPK:MTZPY, OTCPK:APNHY, OTCPK:SFOSF, OTCPK:HLUYY, NYSE:RDY, OTCPK:IPSEY, OTCPK:HKMPY, NYSE:MNK, NYSE:VRX, OTCPK:HYPMY, NAS:OPK, NYSE:TARO » details
Traded in other countries:A60.Germany, AGN N.Mexico,
Allergan PLC is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and distributing generic, brand and biosimilar products.

Allergan PLC, formerly known as Actavis PLC was incorporated in Ireland on May 16, 2013. It is an integrated specialty pharmaceutical company. The Company is engaged in development, manufacturing, marketing, sale and distribution of generic, branded generic, brand name, biosimilar and over-the-counter pharmaceutical products. It also develops and out-license generic pharmaceutical products in Europe through its Medis third-party business. It operates in three segments, Pharma, Specialty Brands and Anda Distribution. The Pharma segment includes off-patent pharmaceutical products that are therapeutically equivalent to proprietary products. The Specialty Brands segment includes patent-protected products and certain trademarked off-patent products that the Company sells and markets as brand pharmaceutical products. The Anda Distribution segment distributes generic and brand pharmaceutical products manufactured by third parties, as well as by the Company to independent pharmacies, pharmacy chains, pharmacy buying groups and physicians' offices. It competes with generic manufacturers of pharmaceutical products. It is subject to extensive, complex and evolving regulation by the federal government, the FDA, and to a lesser extent, by the U.S. Drug Enforcement Administration Occupational Safety and Health Administration and state government agencies, as well as by various regulatory agencies in foreign countries where its products or product candidates are being manufactured and/or marketed. The Federal Food, Drug and Cosmetic Act, the Controlled Substances Act and other federal statutes and regulations govern or influence the testing, manufacturing, packing, labeling, storing, record keeping, safety, approval, advertising, promotion, sale and distribution of its products.

Guru Investment Theses on Allergan PLC

Weitz Funds Comments on Allergan - Jan 26, 2017

Allergan (NYSE:AGN) is a global specialty pharmaceutical company focusing on the development, manufacturing, marketing and distribution of brand name, biosimilar and over-the-counter pharmaceutical products. Following a brief post-election rally, the majority of the biopharmaceutical sector retreated to prior price levels as capital continued to flow out of healthcare and into industries seen as potential beneficiaries of policy shifts under the new administration. After downwardly revising future growth expectations in August and again in early November, Allergan has become a “show me” story. Patent challenges for Restasis (dry eye treatment) and Namenda XR (alzheimer’s drug) may continue to weigh on the stock in the near term, though each contributes only a small percentage of our estimate of the company’s overall intrinsic value. Over the next 3-5 years, we believe the company will have healthy mid-single digit (or better) operating profit growth. 80% of the company’s recently announced $10 billion accelerated share repurchase program is complete at an average price below $200 per share. We believe this will prove to be a prudent use of excess cash in the long run. Future capital deployment and late-stage pipeline success remain potential positives over the next 12 -24 months. We continue to believe Allergan shares present compelling value at current prices.



From Weitz Investment Management's Value Fund fourth quarter 2016 commentary.



Check out Wallace Weitz latest stock trades

Weitz Funds Comments on Allergan - Nov 11, 2016

Allergan (NYSE:AGN) is a global specialty pharmaceutical company focusing on the development, manufacturing, marketing and distribution of brand name, biosimilar and over-the-counter (OTC) pharmaceutical products. One week after closing the sale of Actavis generics to Teva Pharmaceuticals, Allergan reported mildly disappointing top-line results for the quarter. Importantly, however, Allergan’s “core” products continue to grow nicely, with five of the company’s seven core therapeutic categories growing by double digits (in constant currency) versus the prior year. Our base case valuation of $350-360 per share does not depend on Allergan hitting CEO Brent Saunders’ goal of double- digit organic growth. However, strong, high single-digit organic sales growth appears achievable, as the company’s recently launched products continue to scale. One near-term positive of a lower share price is that Allergan’s $5 billion in share repurchases between now and year end will go further, and deployment of a portion of the company’s nearly $28 billion in cash remains a possible catalyst for the stock. The re-emergence of drug pricing as a political issue is not surprising to us as we enter the home stretch of the presidential election. We believe Secretary Clinton’s plan to control and eventually lower prescription drugs costs could negatively impact Allergan’s long-term earnings trajectory (perhaps by $2-3 per share on a base of $18), should she win the election, but with the stock at $240, we believe the risk of permanent loss is low. In short, Allergan’s risk/reward ratio (upside to base case vs. downside to low case) continues to be skewed in favor of the long-term owner.





  • From Weitz Balanced Fund third quarter 2016 commentary.


Check out Wallace Weitz latest stock trades

Daniel Loeb Comments on Akarna Therapeutics - Nov 02, 2016

Akarna Therapeutics TPV was a founding investor in Akarna in Q1 2015. Akarna focuses on the treatment of Nonalcoholic Steatohepatitis (NASH), also known as fatty liver disease. Akarna was attractive for several reasons:



  • Large market opportunity: Epidemiologic studies suggest that NASH affects 2 – 5% of Americans and is believed to be correlated with increasing rates of obesity, diabetes, and high cholesterol. If left untreated, NASH can lead to liver fibrosis, cirrhosis, and, ultimately, end-stage liver disease. Unfortunately, there are no currently approved treatments for NASH.

  • Derisked mechanism of action: Clinical trials with bile acids have validated farnesoid X receptor agonists as a viable therapeutic agent based on clinical and histological biomarkers of the disease. These trials have also demonstrated a clear need for treatments with still improved efficacy and better side effect profiles.

  • Active area of business development: Over the past few years, the sector has seen burgeoning interest in NASH assets with partnerships or acquisitions (e.g., Gilead / Nimbus, Merck / NGM) occurring at attractive valuations.

The team at Akarna identified a potentially best-in-class lead candidate with an attractive pre-clinical profile in in vitro and animal studies. Akarna also secured a broad intellectual property portfolio around the lead compound family.



In August 2016, just 18 months after Akarna was founded, Allergan acquired the company for an upfront payment of $50 million and undisclosed potential clinical, regulatory, and commercial milestones. For Third Point Ventures, our share of the upfront payment reflects a total return of 3.1x our initial investment. If Allergan (NYSE:AGN) successfully develops and commercializes the Akarna drug, the total return on our investment could be meaningfully larger.



From Third Point's third-quarter 2016 commentary.



Check out Daniel Loeb latest stock trades

Jerome Dodson Comments on Allergan - Jul 26, 2016

Allergan (NYSE:AGN), an innovative pharmaceutical company best known for developing Botox, reduced the return by 41 basis points as the stock dropped 13.8% from $268.03 to $231.09. The shares sank after Pfizer terminated its plans to acquire Allergan for $160 billion. Pfizer walked away from the deal because of new rules from the U.S. Treasury that prevent tax-lowering corporate inversions. We used the stock’s weakness to increase our position, since Allergan has an attractive collection of durable brands. We also like the fact that the company is in the process of selling its generic drug unit to Teva for $40 billion, which will enable Allergan to repurchase stock, pay down debt and acquire innovative drug companies.


From Jerome Dodson (Trades, Portfolio)'s Parnassus Fund second quarter 2016 commentary.

Check out Jerome Dodson latest stock trades

Weitz Funds Comments on Allergan - Jul 20, 2016

Allergan (NYSE:AGN) is a global specialty pharmaceutical company focusing on the development, manufacturing, marketing and distribution of generic, brand name, biosimilar and over-the-counter (OTC) pharmaceutical products. The dissolution of Allergan’s merger with Pfizer in April, delays in gaining Federal Trade Commission approval for the sale of its global generics business to TEVA and broader industry concern around prescription drug prices combined to push Allergan’s stock down by 26% during the first half of the calendar year. As we wrote in January, we like the stand-alone Allergan business without the generics business and believe the $ 40 billion sale to TEVA should soon close. There are a number of signs that growth in Allergan’s aesthetics franchise is accelerating, and the company’s key product launches – VIBERZI, VRAYLAR and KYBELLA – appear to be off to healthy starts. The combination of healthy organic growth, debt reduction and meaningful share repurchases should drive per share value creation over our investment horizon. We substantially increased the Fund’s Allergan position during the second quarter at attractive discounts to our business value estimate.



From Weitz Value Fund's Value second quarter 2016 commentary.



Check out Wallace Weitz latest stock trades

Ruane Cunniff Comments on Allergan - Jul 13, 2016

We exited two smaller positions during the quarter. While Allergan (NYSE:AGN) has a stronger collection of assets and far better outlook than Valeant, we suspect many drug makers will face increasing pressure from health care payers who need to reduce the relentless double-digit inflation rate for branded pharmaceuticals.

From Ruane Cunniff (Trades, Portfolio)'s Sequoia Fund second quarter 2016 shareholder letter.

Check out Ruane Cunniff latest stock trades

Baron Funds Comments on Allergan plc - May 06, 2016

Our conviction to buy Allergan plc (NYSE:AGN) in the first quarter relied on differentiation of Allergan from its specialty pharmaceutical peers (Valeant, Endo, Mallinckrodt) given the quality of its asset mix (Botox, glaucoma drugs, breast implants, aesthetics, etc.) and its non-reliance on distasteful price increases for growth. Admittedly, we were aware of the potential upside to the Pfizer deal and were disappointed with the Treasury’s actions to stem tax inversions. Regardless, we were comfortable with Allergan as a stand-alone company, given the above base business married to the pending closure of the sale of Allergan’s generics portfolio to Teva for approximately $40 billion. This deal (pending over the next quarters) will help drive Allergan’s M&A efforts towards obtaining a more biotech like growth profile, which should both drive increases in top/bottom-line growth and expand the multiple at which investors are willing to value Allergan’s business. However, while our initial thesis remains intact, the entire specialty pharmaceutical space has re-rated given the above-mentioned bad actors. This has pressured the entire space, and we decided to exit specialty pharmaceuticals and focus on the more innovative biotech space going forward.





From Baron Opportunity Fund first quarter 2016 commentary.







Check out Ron Baron latest stock trades

Weitz Funds Comments on Allergan - Apr 25, 2016

Allergan (NYSE:AGN) is a global specialty pharmaceutical company focused on the development, manufacturing, marketing and distribution of generic, brand name, biosimilar and over-the-counter pharmaceutical products. A combination of factors contributed to the decline in Allergan’s stock during the quarter, including continued discussions of potential drug price regulation, regulatory delays in closing the company’s sale of its generic drug operations to TEVA and uncertainty around the viability of the proposed merger with Pfizer (which, subsequent to quarter end, has officially been called off). We believe the risk of the TEVA transaction falling through is low, and the company’s collection of durable growth assets, management acumen and balance sheet optionality create multiple paths for durable shareholder value creation in the years ahead. We added to our position during the quarter.



From Weitz Funds' Research Fund commentary 1st quarter.



Check out Wallace Weitz latest stock trades

Bernard Horn Comments on Allergan PLC - Mar 21, 2016

In healthcare, pharmaceutical maker Allergan PLC (NYSE:AGN) was expected to achieve 80% of an estimated $1.8 billion in synergies stemming from recent acquisitions by the end of the first quarter of 2016. With valuable drugs like Botox and a rich R&D pipeline, Allergan was approached by Pfizer. Pfizer held preliminary and friendly discussions to acquire Allergan, which will offer Pfizer a low tax domicile in Dublin.

From Bernard Horn (Trades, Portfolio)'s Global Value Fund annual letter 2015.



Check out Bernard Horn latest stock trades

GAMCO Global Growth Fund Comments on Allergan Plc - Feb 22, 2016

Allergan plc (NYSE:AGN) (3.4% of net assets as of December 31, 2015) (AGN – $312.50 – NYSE) markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally. A combination with Pfizer is pending and should close sometime this year.





From the GAMCO Global Growth Fund fourth quarter 2015 commentary.



Check out Mario Gabelli latest stock trades

Baron Funds Comments on Allergan - Jan 27, 2016

Allergan plc (NYSE:AGN) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing brand, generic and biosimilar products. Probably best known for its Botox, Allergan has undergone a massive, M&A driven transformation after combinations with Forest Labs ($25 billion) and Actavis ($66 billion) have created a $120 billion behemoth. In the process, the company has upgraded its quality of earnings and diversified away from legacy dermatology and ophthalmology businesses. Our analysis suggested that Allergan’s earnings could rise from about $15/share this year, to about $25/share in five years making it attractive enough to initiate a small position. Late in the fourth quarter, Pfizer made a long speculated cash and stock bid to acquire Allergan at about a 20% premium to its price. So-called “tax inversion” is one of the goals analysts believe Pfizer was after in attempting to acquire Allergan, and various U.S. politicians have spoken out about the need to try and prevent these kinds of transactions. We believe Allergan should do well regardless of whether this deal will go through or not (although, we think that it will) as the stock did not move and continues to trade at about 20% discount to Pfizer’s offer price.



From the Baron Fifth Avenue Growth Fund Fourth Quarter 2015 Letter.



Check out Ron Baron latest stock trades

Weitz Funds Comments on Allergan - Jan 25, 2016

Allergan (NYSE:AGN) is a global specialty pharmaceutical company focusing on the development, manufacturing, marketing and distribution of generic, brand name, biosimilar and over-the-counter (OTC) pharmaceutical products. Shares of Allergan were volatile during the quarter, providing us the opportunity to meaningfully increase our position at attractive prices. Following several months of speculation, Pfizer and Allergan announced their intention to combine on November 23rd. Assuming the deal is consummated as presently structured, Allergan shareholders would receive 11.3 shares of the combined Pfizer-Allergan for each existing Allergan share. Potential tax and regulatory hurdles remain, but we are optimistic on Allergan’s business prospects in either scenario - standalone or in combination with Pfizer. We have generally positive impressions from ongoing diligence on Pfizer’s business.



From the Weitz Funds' Research Fund shareholder letter for fourth quarter 2015.



Check out Wallace Weitz latest stock trades

Wallace Weitz Comments on Allergan - Jan 22, 2016

Allergan (NYSE:AGN) is a global specialty pharmaceutical company focusing on the development, manufacturing, marketing and distribution of generic, brand name, biosimilar and over-the-counter (OTC) pharmaceutical products. Shares of Allergan were volatile during the quarter, providing us the opportunity to meaningfully increase our position at attractive prices. Following several months of speculation, Pfizer and Allergan announced their intention to combine on November 23rd. Assuming the deal is consummated as presently structured, Allergan shareholders would receive 11.3 shares of the combined Pfizer-Allergan for each existing Allergan share. Potential tax and regulatory hurdles remain, but we are optimistic on Allergan’s business prospects in either scenario - standalone or in combination with Pfizer. We have generally positive impressions from ongoing diligence on Pfizer’s business.

From Wallace Weitz (Trades, Portfolio)'s fourth quarter 2015 Value Fund commentary.

Check out Wallace Weitz latest stock trades

Wallace Weitz Comments on Allergan - Oct 27, 2015

Allergan (NYSE:AGN) is a global specialty pharmaceutical company focusing on the development, manufacturing, marketing and distribution of generic, brand name, biosimilar and over-the-counter (OTC) pharmaceutical products. Formerly Actavis, the “new” Allergan is a collection of significant acquisitions over the past 4-5 years, including Watson Pharmaceuticals, Warner Chilcott, Forest Laboratories and legacy Allergan. In late July, Allergan announced the divestiture of its global generics business to Teva for $40.5B, which we believe is a terrific sale price for AGN. Assuming the transaction closes as expected, Allergan should begin calendar 2016 as a pure-play branded pharmaceutical manufacturer with high single digit annual growth prospects and a reloaded balance sheet. We believe the stock is compelling at current prices.



From Wallace Weitz (Trades, Portfolio)'s 3Q 2015 commentary.

Check out Wallace Weitz latest stock trades

Top Ranked Articles about Allergan PLC

Weitz Funds Comments on Allergan Guru stock highlight
Allergan (NYSE:AGN) is a global specialty pharmaceutical company focusing on the development, manufacturing, marketing and distribution of brand name, biosimilar and over-the-counter pharmaceutical products. Following a brief post-election rally, the majority of the biopharmaceutical sector retreated to prior price levels as capital continued to flow out of healthcare and into industries seen as potential beneficiaries of policy shifts under the new administration. After downwardly revising future growth expectations in August and again in early November, Allergan has become a “show me” story. Patent challenges for Restasis (dry eye treatment) and Namenda XR (alzheimer’s drug) may continue to weigh on the stock in the near term, though each contributes only a small percentage of our estimate of the company’s overall intrinsic value. Over the next 3-5 years, we believe the company will have healthy mid-single digit (or better) operating profit growth. 80% of the company’s recently announced $10 billion accelerated share repurchase program is complete at an average price below $200 per share. We believe this will prove to be Read more...
Weekly CEO Buys Highlights Insiders purchase Aramark, Allergan, Brixmor, New Media, Pennant
According to GuruFocus’ Insider Data, these are the largest CEO buys during the past week. The overall trend of purchases is illustrated in the chart below: Read more...
Weekly Top Insider Buys Highlight for Week of Nov. 18 Largest Insider Buys for Allergan, Mondelez International, Enterprise Products Partners and Occidental Petroleum
Largest Insider Buys for Allergan PLC (NYSE:AGN), Mondelez International Inc. (NASDAQ:MDLZ), Enterprise Products Partners LP (NYSE:EPD) and Occidental Petroleum Corp (NYSE:OXY). Read more...
Weitz Funds Comments on Allergan Guru stock highlight
Allergan (NYSE:AGN) is a global specialty pharmaceutical company focusing on the development, manufacturing, marketing and distribution of brand name, biosimilar and over-the-counter (OTC) pharmaceutical products. One week after closing the sale of Actavis generics to Teva Pharmaceuticals, Allergan reported mildly disappointing top-line results for the quarter. Importantly, however, Allergan’s “core” products continue to grow nicely, with five of the company’s seven core therapeutic categories growing by double digits (in constant currency) versus the prior year. Our base case valuation of $350-360 per share does not depend on Allergan hitting CEO Brent Saunders’ goal of double- digit organic growth. However, strong, high single-digit organic sales growth appears achievable, as the company’s recently launched products continue to scale. One near-term positive of a lower share price is that Allergan’s $5 billion in share repurchases between now and year end will go further, and deployment of a portion of the company’s nearly $28 billion in cash remains a possible catalyst for the stock. The re-emergence of drug pricing Read more...
John Paulson’s Health Care Stocks Drop Far Below Sector Return Losses and redemptions mount despite Paulson's strong record
After years of uneven returns following his multi-billion-dollar profits shorting the subprime mortgage market in 2007, Paulson’s pain intensified this year as his outsized bet on the wrong health care stocks scuttled returns and spooked investors. Read more...
Ruane Cunniff Cuts Allergan, Berkshire, IBM Largest sale by the guru in 2nd quarter
Ruane Cunniff (Trades, Portfolio) is a value investor focused on the intrinsic value of business. It manages a portfolio composed of 118 stocks with a total value of $10.499 billion. During the second quarter the guru traded the following stocks. Read more...
Robert Bruce Invests in Allergan in 2nd Quarter Guru made fewest quarterly transactions in more than a year
Robert Bruce (Trades, Portfolio) of Bruce & Co. made transactions in five stocks in the second quarter, his fewest in more than a year, but the guru’s activity included deals in some well-known stocks, such as pharmaceutical company Allergan PLC (NYSE:AGN) and Amerco Inc. (NASDAQ:UHAL), the company that owns U-Haul. Read more...
Allergan: An Undervalued Powerhouse After selling its generic units to Teva, Allergan has room for growth
Allergan (NYSE:AGN) is one of the largest pharmaceutical powerhouses, operating in many areas including eye care, facial aesthetics, plastic surgery, skin care and neuroscience and urology. Allergan’s history is quite interesting as the company has grown via many big acquisitions. Read more...
Carl Icahn Buys Allergan Pharmaceutical company is new holding
During the second quarter, Carl Icahn (Trades, Portfolio) of Icahn Capital Management acquired a new holding in Allergan PLC (NYSE:AGN). Read more...
David Tepper Raises Bet on Allergan, Adds 2 New Positions in Latest Quarter Tepper made significant increase to Allergan
During the most recent quarter, world-renowned investor David Tepper (Trades, Portfolio) showed staunch conviction on Allergan while adding just two new positions to his Appaloosa Management portfolio. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 6.61
AGN's P/E(ttm) is ranked higher than
94% of the 568 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.40 vs. AGN: 6.61 )
Ranked among companies with meaningful P/E(ttm) only.
AGN' s P/E(ttm) Range Over the Past 10 Years
Min: 5.07  Med: 25.06 Max: 366.63
Current: 6.61
5.07
366.63
Forward P/E 15.46
AGN's Forward P/E is ranked higher than
50% of the 88 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.46 vs. AGN: 15.46 )
Ranked among companies with meaningful Forward P/E only.
N/A
Price/Owner Earnings (ttm) 4.32
AGN's Price/Owner Earnings (ttm) is ranked higher than
95% of the 300 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.72 vs. AGN: 4.32 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
AGN' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 3.31  Med: 18.51 Max: 1279.04
Current: 4.32
3.31
1279.04
P/B 1.22
AGN's P/B is ranked higher than
84% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.02 vs. AGN: 1.22 )
Ranked among companies with meaningful P/B only.
AGN' s P/B Range Over the Past 10 Years
Min: 0.87  Med: 1.74 Max: 5.9
Current: 1.22
0.87
5.9
P/S 6.35
AGN's P/S is ranked lower than
71% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.06 vs. AGN: 6.35 )
Ranked among companies with meaningful P/S only.
AGN' s P/S Range Over the Past 10 Years
Min: 0.99  Med: 1.84 Max: 17.57
Current: 6.35
0.99
17.57
PFCF 78.18
AGN's PFCF is ranked lower than
84% of the 226 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 22.72 vs. AGN: 78.18 )
Ranked among companies with meaningful PFCF only.
AGN' s PFCF Range Over the Past 10 Years
Min: 6.62  Med: 15.16 Max: 78.18
Current: 78.18
6.62
78.18
POCF 65.11
AGN's POCF is ranked lower than
88% of the 295 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.98 vs. AGN: 65.11 )
Ranked among companies with meaningful POCF only.
AGN' s POCF Range Over the Past 10 Years
Min: 5.97  Med: 12.56 Max: 65.11
Current: 65.11
5.97
65.11
EV-to-EBITDA 22.13
AGN's EV-to-EBITDA is ranked lower than
64% of the 600 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.72 vs. AGN: 22.13 )
Ranked among companies with meaningful EV-to-EBITDA only.
AGN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -224.1  Med: 11.7 Max: 386.1
Current: 22.13
-224.1
386.1
Shiller P/E 55.15
AGN's Shiller P/E is ranked lower than
60% of the 158 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 47.37 vs. AGN: 55.15 )
Ranked among companies with meaningful Shiller P/E only.
AGN' s Shiller P/E Range Over the Past 10 Years
Min: 18.96  Med: 54.31 Max: 2307.73
Current: 55.15
18.96
2307.73
Days Inventory 157.94
AGN's Days Inventory is ranked lower than
70% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.19 vs. AGN: 157.94 )
Ranked among companies with meaningful Days Inventory only.
AGN' s Days Inventory Range Over the Past 10 Years
Min: 75.66  Med: 121.54 Max: 369.82
Current: 157.94
75.66
369.82
Days Sales Outstanding 58.49
AGN's Days Sales Outstanding is ranked higher than
66% of the 628 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.32 vs. AGN: 58.49 )
Ranked among companies with meaningful Days Sales Outstanding only.
AGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.05  Med: 60.25 Max: 197.04
Current: 58.49
39.05
197.04
Days Payable 49.30
AGN's Days Payable is ranked lower than
68% of the 574 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.12 vs. AGN: 49.30 )
Ranked among companies with meaningful Days Payable only.
AGN' s Days Payable Range Over the Past 10 Years
Min: 28.03  Med: 76.38 Max: 109.48
Current: 49.3
28.03
109.48

Buy Back

vs
industry
vs
history
Forward Dividend Yield 1.13
AGN's Forward Dividend Yield is ranked lower than
66% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.35 vs. AGN: 1.13 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 0.09
AGN's Yield on cost (5-Year) is ranked lower than
98% of the 764 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.14 vs. AGN: 0.09 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
AGN' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.08  Med: 0.32 Max: 0.63
Current: 0.09
0.08
0.63
3-Year Average Share Buyback Ratio -29.10
AGN's 3-Year Average Share Buyback Ratio is ranked lower than
87% of the 436 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.40 vs. AGN: -29.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AGN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -45.6  Med: -6 Max: 2
Current: -29.1
-45.6
2

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 1.22
AGN's Price/Tangible Book is ranked higher than
86% of the 747 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.65 vs. AGN: 1.22 )
Ranked among companies with meaningful Price/Tangible Book only.
AGN' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.03  Med: 7.62 Max: 250.29
Current: 1.22
1.03
250.29
Price/Projected FCF 1.17
AGN's Price/Projected FCF is ranked higher than
82% of the 320 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. AGN: 1.17 )
Ranked among companies with meaningful Price/Projected FCF only.
AGN' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.6  Med: 1.19 Max: 2.96
Current: 1.17
0.6
2.96
Price/Median PS Value 3.45
AGN's Price/Median PS Value is ranked lower than
91% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. AGN: 3.45 )
Ranked among companies with meaningful Price/Median PS Value only.
AGN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.67  Med: 1.47 Max: 5.54
Current: 3.45
0.67
5.54
Earnings Yield (Greenblatt) (%) -1.40
AGN's Earnings Yield (Greenblatt) (%) is ranked lower than
72% of the 835 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. AGN: -1.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AGN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -1.4  Med: 6.1 Max: 12.3
Current: -1.4
-1.4
12.3
Forward Rate of Return (Yacktman) (%) 7.36
AGN's Forward Rate of Return (Yacktman) (%) is ranked lower than
54% of the 358 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.67 vs. AGN: 7.36 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
AGN' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -5.2  Med: 7.4 Max: 16.1
Current: 7.36
-5.2
16.1

More Statistics

Revenue (TTM) (Mil) $14,967
EPS (TTM) $ 37.41
Beta1.34
Short Percentage of Float4.05%
52-Week Range $184.50 - 301.32
Shares Outstanding (Mil)374.95

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 15,564 16,576 17,658
EPS ($) 16.12 17.92 20.22
EPS w/o NRI ($) 16.12 17.92 20.22
EPS Growth Rate
(3Y to 5Y Estimate)
12.71%
Dividends Per Share ($) 1.87 1.54 1.70
» More Articles for AGN

Headlines

Articles On GuruFocus.com
David Tepper Invests Heavily in Pharma in 4th Quarter Feb 16 2017 
Where Seth Klarman Sees Value in Today’s Market Feb 15 2017 
Daniel Loeb Drops Pharma, Picks Up Rate-Sensitive Financials Feb 13 2017 
How BioVie, Conatus and PhaseRX Tackle Liver Diseases Feb 08 2017 
Daniel Loeb's Third Point Hedge Fund 4th Quarter Commentary Feb 02 2017 
Weitz Funds Comments on Allergan Jan 26 2017 
Teva Is a Hold Nov 30 2016 
Weekly CEO Buys Highlight Nov 29 2016 
Weekly Top Insider Buys Highlight for Week of Nov. 18 Nov 19 2016 
John Griffin Expands Portfolio in 3rd Quarter Nov 16 2016 

More From Other Websites
Riddle Me This; Bendable Market: Best of Kass Feb 17 2017
Stull, Stull & Brody is Investigating Claims on Behalf of Allergan’s (NYSE:AGN) 401(k) Plan Feb 17 2017
Pharma Stock Roundup: Merck's Alzheimer's Study Halted, Allergan to Buy ZELTIQ Feb 17 2017
Stress boom to boost drug sales? Feb 16 2017
David Tepper Invests Heavily in Pharma in 4th Quarter Feb 16 2017
5 Ways Allergan Can Keep Up Momentum Feb 15 2017
Tepper's Appaloosa Fund Continues Bet on Drug Companies in Q4 2016 Feb 15 2017
Tepper's Appaloosa triples stake in Allergan Feb 15 2017
Billionaire Dan Loeb’s Biggest Q4 Moves Include Bank-Buying Spree, Selling Allergan (AGN) Feb 15 2017
Medicines360 And Allergan Announce Partnership With Health Centers To Help Address Unintended... Feb 15 2017
What the Smart Money's buying Feb 14 2017
David Tepper Increases Wagers on Drug Companies Feb 14 2017
Bets on financials, pharma power U.S. hedge funds' strong start to year Feb 14 2017
David Tepper's Appaloosa just dropped about $1 billion on 4 pharma stocks Feb 14 2017
Appaloosa Management snaps up Allergan shares in 4th quarter Feb 14 2017
Hologic Follows Allergan, Buying Body-Sculptor Cynosure For $1.65 Bil Feb 14 2017
ETFs with exposure to Allergan Plc : February 14, 2017 Feb 14 2017
Today's Research Reports on Stocks to Watch: Teva Pharmaceutical Industries and Allergan Feb 14 2017
Valeant, Pershing Square to Split Legal Fees on Allergan Lawsuit Feb 14 2017
Teva (TEVA) Tops on Q4 Earnings, Maintains 2017 Guidance Feb 14 2017
Blog Coverage Allergan Acquires ZELTIQ; Set to Expand Presence in the Body Contouring Business Feb 14 2017
Asian shares fall back as investors await comments by Yellen Feb 13 2017
Allergan to buy fat-fighter Zeltiq Aesthetics for $2.48 billion Feb 13 2017
Allergan to buy fat-fighter Zeltiq Aesthetics for $2.48 billion Feb 13 2017
Allergan to buy fat-fighter Zeltiq Aesthetics for $2.48 billion Feb 13 2017
Allergan to spend $2.48 B on CoolSculpting provider Zeltiq Feb 13 2017
US STOCKS-S&P 500 ekes out gain while banks drag on Dow Feb 08 2017
US STOCKS-S&P 500 inches up while banks drag on Dow Feb 08 2017
Allergan reports 4Q loss Feb 08 2017
Acelity Completes Sale of LifeCell to Allergan Feb 01 2017
Pfizer swings to 4Q profit after rough year, hikes 2017 view Jan 31 2017
Trump travel ban stirs faint corporate outcry beyond Silicon Valley Jan 30 2017
Trump travel ban stirs faint corporate outcry beyond Silicon Valley Jan 30 2017
Growing insurance consortium eyes industry-wide blockchain Jan 25 2017
Correction: Drug Prices-Johnson & Johnson story Jan 11 2017
Allergan to Present at Goldman Sachs Healthcare CEOs Unscripted Conference and Provides Preliminary... Jan 05 2017
FDA Accepts For Filing Supplemental New Drug Application (sNDA) For LILETTA®... Jan 04 2017
Allergan Announces FDA Approval of NATRELLE INSPIRA® SoftTouch Breast Implants Jan 03 2017
US stocks inch higher in slow pre-holiday trading Dec 23 2016
Allergan plc Board of Directors Issues Statement on Company's Social Contract with Patients Dec 22 2016
Ironwood and Allergan Report Topline Phase IIb Data Supporting Further Investigation of Linaclotide... Dec 22 2016
Ironwood and Allergan Report Topline Phase IIb Data Supporting Advancement of Linaclotide Colonic... Dec 22 2016
Ironwood and Allergan Report Topline Phase IIb Data Supporting Advancement of Linaclotide Colonic... Dec 22 2016
Ironwood and Allergan Report Topline Phase IIb Data Supporting Further Investigation of Linaclotide... Dec 22 2016
Ironwood and Allergan Report Topline Phase IIb Data Supporting Advancement of Linaclotide Colonic... Dec 22 2016
Ironwood and Allergan Report Topline Phase IIb Data Supporting Further Investigation of Linaclotide... Dec 22 2016
Allergan to buy Acelity's tissue unit LifeCell for $2.9 bln Dec 20 2016
Allergan to buy Acelity's tissue unit LifeCell for $2.9 bln Dec 20 2016
Allergan to Acquire Acelity L.P. Inc.'s LifeCell Corporation for $2.9 Billion Dec 20 2016
Acelity to Sell LifeCell Business Unit to Allergan Dec 20 2016
Acelity to Sell LifeCell Business Unit to Allergan Dec 20 2016
Actavis UK accused of overcharging hydrocortisone drug Dec 16 2016
Actavis UK raised drug prices 12,000 percent, watchdog finds Dec 16 2016
Actavis UK raised drug prices 12,000 pct, watchdog finds Dec 16 2016
Pharma execs weigh in on possible changes under Trump Dec 01 2016
Lilly's drug for Alzheimer's fails big trial; shares drop Nov 23 2016
Allergan Acquires Chase Pharmaceuticals to Expand CNS R&D Pipeline and Build on Commitment to... Nov 22 2016
Allergan Receives FDA Clearance for the XEN® Gel Stent, a New Surgical Treatment for Refractory... Nov 22 2016
Allergan Announces Partnership with Amy Dixon, Elite Paratriathlete, to Improve Patient-Physician... Nov 16 2016
Amgen And Allergan Submit Biosimilar Biologics License Application For ABP 215 To U.S. Food And Drug... Nov 15 2016
Teva trims 2016 outlook on drug launch delays Nov 15 2016
Juniper Pharmaceuticals Monetizes U.S. Crinone Royalty Stream with Allergan Nov 15 2016
REUTERS SUMMIT-Omega's Einhorn sees Trump's policies boosting stocks Nov 14 2016
Adriane M. Brown to Join Allergan plc Board of Directors Nov 14 2016
Allergan Announces Launch of TAYTULLA™ (Norethindrone Acetate and Ethinyl Estradiol Capsules and... Nov 10 2016
Asanko Gold reports Q3 2016 results Nov 07 2016
Asanko Gold Reports Q3 2016 Results Nov 07 2016
Asanko Gold to Proceed With Phase 2A Expansion Nov 03 2016
Teva to sell Allergan's generics business in UK, Ireland for $769 million Oct 05 2016
Teva to sell Allergan's generics business in UK, Ireland for $769 million Oct 05 2016
Teva to sell Allergan's generics business in UK, Ireland for $769 million Oct 05 2016
AstraZeneca licenses inflammatory disease candidate to Allergan Oct 03 2016
US STOCKS-Wall St ends flat with Fed, BOJ up next Sep 20 2016
Akarna Therapeutics Ltd acquired by Allergan plc Sep 20 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)